![]() ![]() The location(s) of each injection (left or right side) should be noted so that prior injection sites can be identified and the next injection can be administered on the opposite side. No more than 3 mL should be administered in a single site. Using aseptic technique, inject the product subcutaneously in the left or right side of the dorsum of the neck cranial to the scapula. ![]() If administration is delayed, gently roll the dosing syringe prior to injection to maintain a uniform suspension and accurate dosing. Dose promptly after drawing into dosing syringe. Withdraw 0.05 mL of suspension/kg body weight (0.023 mL/lb) into an appropriately sized syringe fitted with an 18G or 20G hypodermic needle. Swirl the constituted product vial gently before every use to uniformly re-suspend the microspheres. (See CONSTITUTION PROCEDURES for initial mixing instructions.) ProHeart 12 must be prepared at least 30 minutes prior to the first use by adding the sterile vehicle to the microspheres. *All dogs should be dosed at 0.05 mL suspension/kg body weight (0.023 mL /lb). The following table provides a guide for weight specific dose volumes. To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment. This amount of suspension will provide 0.5 mg moxidectin/kg body weight (0.23 mg/lb). stenocephala may occur sooner than 12 months.ĭose: The recommended subcutaneous dose is 0.05 mL of the constituted suspension/kg body weight (0.023 mL/lb). stenocephala present at the time of treatment. ProHeart 12 eliminates the larval and adult stages of A. When replacing a monthly heartworm preventive product, ProHeart 12 should be given within one month of the last dose of the former medication to avoid a gap in protection. Follow-up treatments may be given every 12 months, if the dog continues to be healthy and without weight loss, to provide continuous year-round protection. For dogs not previously on heartworm preventive or having lapsed beyond 12 months of a prior ProHeart 12 dose, the product should be given within 1 month of exposure to mosquitoes. ProHeart 12 prevents the development of heartworm disease caused by D. The Client Information Sheet is attached to the package insert and available online at for reprinting to provide to the owner. The owner should be advised to observe their dog for adverse drug events including those described on the sheet. ProHeart 12 (moxidectin) Dosage And AdministrationĪlways provide Client Information Sheet and review with owners before administering ProHeart 12. ![]() ProHeart 12 is indicated for the treatment of existing larval and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. ProHeart 12 is indicated for use in dogs 12 months of age and older for the prevention of heartworm disease caused by Dirofilaria immitis for 12 months. The constituted product may appear as a hazy to milky suspension. Each mL of constituted drug product contains 10 mg moxidectin, 9% glyceryl tristearate, 2.25% hydroxypropyl methylcellulose, 0.81% sodium chloride, 0.16% methylparaben, 0.02% propylparaben and 0.004% butylated hydroxytoluene. A clear or translucent appearance of the vehicle is normal. ProHeart 12 (moxidectin) for extended-release injectable suspension consists of two separate vials: one vial contains 10% moxidectin sterile microspheres and the second vial contains a specifically formulated sterile vehicle for constitution with the microspheres. For Extended-Release Injectable Suspension for Dogs ProHeart 12 (moxidectin) Cautionįederal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |